<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1492">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385199</url>
  </required_header>
  <id_info>
    <org_study_id>13807</org_study_id>
    <nct_id>NCT04385199</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma for Patients With COVID-19</brief_title>
  <official_title>The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in
      patients with COVID-19 respiratory disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in respiratory disease</measure>
    <time_frame>day 1 post transfusion</time_frame>
    <description>For intubated patients improvement in PaO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in respiratory disease</measure>
    <time_frame>day 3 post transfusion</time_frame>
    <description>For intubated patients improvement in PaO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in respiratory disease</measure>
    <time_frame>day 5 post transfusion</time_frame>
    <description>For intubated patients improvement in PaO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in respiratory disease</measure>
    <time_frame>day 7 post transfusion</time_frame>
    <description>For intubated patients improvement in PaO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in respiratory disease</measure>
    <time_frame>day 14 post transfusion</time_frame>
    <description>For intubated patients improvement in PaO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in respiratory disease</measure>
    <time_frame>day 28 post transfusion</time_frame>
    <description>For intubated patients improvement in PaO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in respiratory disease</measure>
    <time_frame>7 days</time_frame>
    <description>For non intubated patients time to intubation post transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>28 days</time_frame>
    <description>ICU length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>28 days</time_frame>
    <description>Hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator days</measure>
    <time_frame>28</time_frame>
    <description>Duration of time on ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of convalescent plasma</measure>
    <time_frame>During transfusion, 1 day post-transfusion</time_frame>
    <description>Adverse transfusion events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic improvement</measure>
    <time_frame>3 days post transfusion</time_frame>
    <description>Improvement in Chest X Ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic improvement</measure>
    <time_frame>28 days post transfusion</time_frame>
    <description>Improvement in Chest X Ray</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Coronavirus</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Convalescent plasma 200mL transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy for COVID-19 disease as defined by institutional protocols</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>One 200mL transfusion of ABO compatible convalescent plasma over 3 hours</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 with one or more of the following: Dyspnea Respiratory rate &gt;= 30 breaths/min
             Oxygen saturation &lt;=93% PaO2/FiO2 &lt;300 Bilateral airspace opacities on chest
             radiograph at 24 to 48 hours

        Exclusion Criteria:

          -  Acute myocardial infarction in past 30 days Acute stroke in past 30 days VV ECMO VA
             ECMO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geneva Tatem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneva Tatem, MD</last_name>
    <phone>313-587-6775</phone>
    <email>gtatem1@hfhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneva Tatem, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 9, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Geneva Tatem</investigator_full_name>
    <investigator_title>Associate Clinical Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

